Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

First Celsis results disclose six-month loss

Paul Durman
Tuesday 02 November 1993 19:02 EST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

CELSIS INTERNATIONAL, a biotechnology company that uses an enzyme found in fireflies to detect bacteria, yesterday reported a first-half loss of pounds 560,000, its first results since coming to the market in July, writes Paul Durman.

The digital device that makes use of Celsis's technology will not be launched until next autumn, so sales were only pounds 79,000 in the first half. The company hopes its system will replace the century-old method of agar jelly testing for microbes. It hopes to cut testing times to a day instead of the two to seven days needed with agar plates.

Celsis has launched five 'spearhead' products to help to establish its reputation with prospective customers. One kit is being used by Unilever to test for bacteria in shampoos, soaps and creams. Others are used to monitor water quality, hygiene in the food and drink industry and the quality of raw material used in pharmaceutical production.

Tony Martin, Celsis' chief executive, does not expect significant sales from these products. When launched, the digital system - 'it looks like a Rubik's cube' - will be tailored to the needs of the particular customer.

Celsis raised pounds 12.4m from its float to fund its research.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in